Skip to main content

Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Volume
Day Low150.83
Day High152.76
Open:151.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDFRefinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDFStockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Premium PDFValueEngine

Press & news

Latest News

More Stories
Better Buy: AbbVie vs. Johnson & Johnson
Motley Fool - Sat Mar 25, 4:30AM CDT
Motley Fool
Sat Mar 25, 4:30AM CDT
These pharma giants beat the bear market last year.
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Newswire.ca - Thu Mar 23, 4:07PM CDT
Newswire.ca
Thu Mar 23, 4:07PM CDT
/CNW/ - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that Health Canada has issued a Notice of Compliance (NOC) authorizing the...
Have $1,000? 2 Smart Stocks to Buy This Month
Motley Fool - Thu Mar 23, 9:15AM CDT
Motley Fool
Thu Mar 23, 9:15AM CDT
The market is still giving investors great opportunities to buy exceptional companies.

Latest Articles

Bristol Myers, Pfizer, AbbVie drugs likely to face U.S. price negotiation
Market movers: Stocks that saw action on Tuesday - and why
Johnson & Johnson expects hit from high inflation, China’s COVID-19 outbreak to carry into 2023
What to watch out for when investing in spin-offs
Investors face a thick cloud of gloom. But that doesn’t mean contrarians are buying stocks by the truckload
Market movers: Stocks that saw action on Tuesday - and why
Johnson & Johnson to buy heart pump maker Abiomed for US$16.6-billion
Johnson & Johnson looks at job cuts despite weathering inflation impact
Wall Street rally throws spotlight on reports from Tesla, Netflix
Why this portfolio manager thinks dividend-paying companies will be more important in times of inflation
As U.S. markets churn, some stick with rare 2022 winner: energy shares
Johnson & Johnson reaches nearly US$205-million settlement in Australian pelvic mesh class action

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2023.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2023 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.